The FDA has approved a new COVID-19 vaccine developed by Moderna, offering a lower-dose option aimed at older adults and people with underlying health risks. The vaccine, named mNexspike, is part of a ...

Moderna’s seasonal influenza vaccine met its main goal in a large Phase 3 trial, reducing the risk of influenza-like illness in people 50 years and older by 27% compared with those given a marketed ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The new low-dose vaccine is one-fifth the size of ...

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 and older, as well as people ages 12 to 64 with at least one medical ...

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...

Moderna MRNA-6.53%decrease; red down pointing triangle was once a darling of the first Trump administration, which went to great lengths to help the company develop its Covid-19 vaccine that protected ...